Overnight positions

Overnight positions $CHP $CUR $CYCC $KFS $PAL

CYTX setup

VG setup

HAFC intraday

Watch for a breakout folks!

Trading ideas for April 15, 2010

GMO


SBSA

Overnight positions charts update

$aria $arwr $ent $mni $pacr $pal $rfmd $xxia

ARIA


ENT


MNI


PACR


PAL


RFMD


XXIA


It's been a lllooooong ass while since I have done overnight positions gap up/continuation plays. Very excited to see my results. Good luck everyone!

Overnight positions

$aria $arwr $ent $mni $pacr $pal $rfmd $xxia

5%-10% each.

I will update Charts tonight. Great day today overall with big winners like $CHCI $XNPT...etc

Happy Trading

CHCI Wins the day

Premarket Alert:



2 hours after open:


Follow me on twitter @tradermarket247

Trading ideas for April 14, 2010

WCBO


XNPT



CHCI

AMD setup

CLSN update

Yesterday's alert.



Today the stock is up another 50 cents since my alert from yesterday.


Again, congrats to all share holders.

EK setup

Tues setup

DCTH's Phase III Trial Data to be Presented

NEW YORK, April 13 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq:DCTH - News), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine and a lead Principal Investigator of the Phase III trial, will present the abstract on June 5 at 3:30pm CT, during the Melanoma/Skin Cancer – Oral Abstract Session. The company expects to report top-line results from the trial later this month.

"ASCO's invitation to present at the podium represents a tremendous achievement for the clinicians leading our Phase III trial," said Eamonn P. Hobbs, Delcath's President and CEO. "The invitation illustrates the increasing interest in the Delcath PHP System™ as well as the data generated from the trial within the oncology clinician community. We look forward to Dr. Pingpank sharing this data and thank all of the patients and physicians for their involvement in this groundbreaking study."

Congrats for those who are still holding since alert.

HEPI setup

Watch it folks! I already bought some at $0.99. (Trade at your own risk)

Happy trading.

CLSN

My last Top 3 buy and hold stock of 2010 finally making a move today! $5 should be coming anytime now.